Natural Vascular Scaffold (NVS) Therapy for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Mar 2018
At a glance
- Drugs Peripheral vascular disorder therapeutics Alucent Biomedical (Primary)
- Indications Peripheral vascular disorders
- Focus Therapeutic Use
- Sponsors Alucent Biomedical
- 01 Mar 2018 According to an Alucent Biomedical company website, Alucent Medical changed its name to Alucent Biomedical.
- 29 Nov 2017 Planned End Date changed from 3 Jun 2019 to 25 Jun 2018.
- 29 Nov 2017 Planned primary completion date changed from 3 Jun 2019 to 25 Jun 2018.